← Leaderboards
Shan Lu
Univ Of Massachusetts Med Sch Worcester
$23,520,369
Attributed
$25,561,451
Total exposure
17
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.4M · FY2006–19$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$51,033,152 · 19
By mechanism
U19$29,675,095 · 5
P01$12,953,911 · 3
R01$4,599,626 · 2
U01$2,742,328 · 2
R21$440,000 · 2
R56$284,375 · 1
Top collaborators
- William F Degrado4 shared
- Jose Nieva4 shared
- Jamie K Scott4 shared
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Egil Lien$14,174,464
- Sanjay Ram$21,500,867
- Li Li$1,025,938
- Susan L Swain$26,012,075
- Thomas C Greenough$4,301,808
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsProgramsHiv-1Hiv VaccineAntibodiesImmunogenicityVaccinesEnv Gene ProductsVaccine DevelopmentImmunizationPre-ClinicalClinical ResearchNeutralizing AntibodyBaseAntigensAntibody FormationDesignGenesUnited States National Institutes Of HealthTechnologyImmune ResponseDrug FormulationsNonhuman PrimateSerum
Grant awards (60)
Protein Core$214,565
U19 · FY2019 · AI · contact PI
Protein Core$401,998
U19 · FY2018 · AI · contact PI
Protein Core$510,559
U19 · FY2017 · AI · contact PI
Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulati$701,825
U19 · FY2016 · AI · contact PI
Optimization of HIV vaccines for the induction of cross-reactive antibodies$701,825
U19 · FY2016 · AI · contact PI
Protein Core$469,711
U19 · FY2016 · AI · contact PI
Vaccines that Replicate the Neutralization-Competent Structure of the gp41 MPER$693,593
R01 · FY2015 · AI
Protein Core$447,875
U19 · FY2015 · AI · contact PI
Vaccines that Replicate the Neutralization-Competent Structure of the gp41 MPER$678,372
R01 · FY2014 · AI
Optimization of HIV vaccines for the induction of cross-reactive antibodies$2,947,202
U19 · FY2013 · AI · contact PI
Administrative Core$2,558,935
U19 · FY2013 · AI · contact PI
Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulati$2,343,029
U19 · FY2013 · AI · contact PI
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env$2,026,557
P01 · FY2013 · AI · contact PI
Vaccines that Replicate the Neutralization-Competent Structure of the gp41 MPER$648,324
R01 · FY2013 · AI
CD4bs antigenicity, neutralization and immunogenicity of primary HIV-1 Env$431,875
P01 · FY2013 · AI · contact PI
Administrative Core$122,953
P01 · FY2013 · AI · contact PI
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env$2,007,348
P01 · FY2012 · AI · contact PI
Optimization of HIV vaccines for the induction of cross-reactive antibodies$1,372,884
U19 · FY2012 · AI · contact PI
Administrative Core$1,075,604
U19 · FY2012 · AI · contact PI
CD4bs antigenicity, neutralization and immunogenicity of primary HIV-1 Env$712,007
P01 · FY2012 · AI · contact PI
Vaccines that Replicate the Neutralization-Competent Structure of the gp41 MPER$701,154
R01 · FY2012 · AI
Administrative Core$218,048
P01 · FY2012 · AI · contact PI
Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulati$203,715
U19 · FY2012 · AI · contact PI
Optimization of HIV vaccines for the induction of cross-reactive antibodies$6,050,390
U19 · FY2011 · AI · contact PI
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env$1,975,833
P01 · FY2011 · AI · contact PI
Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulati$1,709,520
U19 · FY2011 · AI · contact PI
Administrative Core$1,645,297
U19 · FY2011 · AI · contact PI
CD4bs antigenicity, neutralization and immunogenicity of primary HIV-1 Env$427,621
P01 · FY2011 · AI · contact PI
Multi-gene Subunit Vaccine Platform Against Y. pestis$411,207
U01 · FY2011 · AI · contact PI
Administrative Core$178,727
P01 · FY2011 · AI · contact PI
Optimization of HIV vaccines for the induction of cross-reactive antibodies$2,366,186
U19 · FY2010 · AI · contact PI
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env$1,852,576
P01 · FY2010 · AI · contact PI
Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulati$461,755
U19 · FY2010 · AI · contact PI
Multi-gene Subunit Vaccine Platform Against Y. pestis$423,405
U01 · FY2010 · AI · contact PI
CD4bs antigenicity, neutralization and immunogenicity of primary HIV-1 Env$396,258
P01 · FY2010 · AI · contact PI
Administrative Core$353,489
U19 · FY2010 · AI · contact PI
Administrative Core$176,725
P01 · FY2010 · AI · contact PI
Polyvalent DNA Plus Protein HIV Vaccines$149,886
R01 · FY2010 · AI · contact PI
Optimization of HIV vaccines for the induction of cross-reactive antibodies$2,313,313
U19 · FY2009 · AI · contact PI
Induction of neutralizing antibodies targeting CD4 binding region of HIV-1 Env$1,857,587
P01 · FY2009 · AI · contact PI
Polyvalent DNA Plus Protein HIV Vaccines$520,093
R01 · FY2009 · AI · contact PI
Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulati$466,211
U19 · FY2009 · AI · contact PI
Multi-gene Subunit Vaccine Platform Against Y. pestis$415,947
U01 · FY2009 · AI · contact PI
CD4bs antigenicity, neutralization and immunogenicity of primary HIV-1 Env$397,588
P01 · FY2009 · AI · contact PI
Administrative Core$359,207
U19 · FY2009 · AI · contact PI
Administrative Core$172,208
P01 · FY2009 · AI · contact PI
Polyvalent DNA Plus Protein HIV Vaccines$408,176
R01 · FY2008 · AI · contact PI
Multi-gene Subunit Vaccine Platform Against Y. pestis$402,600
U01 · FY2008 · AI · contact PI
Polyvalent DNA Plus Protein HIV Vaccines$405,707
R01 · FY2007 · AI · contact PI
Polyvalent DNA Plus Protein HIV Vaccines$394,321
R01 · FY2006 · AI · contact PI
Development of multi-antigen subunit SARS vaccines$284,375
R56 · FY2006 · AI · contact PI
IMMUNOGENICITY OF SARS-COV DNA VACCINES IN COMMON MARMOSETS$34,958
P51 · FY2006 · RR · contact PI
Multi-gene plague vaccine with expanded protection$538,990
U01 · FY2004 · AI
IMMUNOGENICITY OF GB VIRUS-B DNA VACCINES IN MARMOSETS$35,475
P51 · FY2004 · RR
Multi-gene plague vaccine with expanded protection$550,179
U01 · FY2003 · AI
MUCOSAL INFECTION MODEL WITH SHIV PROVIRAL DNA SEQUENCE BY A GENE GUN$101,403
P51 · FY2003 · RR
IMMUNOGENICITY OF HIV DNA VACCINE$84,618
R29 · FY2001 · AI
PRIMARY HIV-1 ENV ANTIGENS WITH DEGLYCOSYLATED VI LOOP$234,000
R21 · FY2000 · AI
GENE GUN MEDIATED MUCOSAL INFECTION WITH PROVIRAL DNAS$206,000
R21 · FY2000 · AI
IMMUNOGENICITY OF HIV DNA VACCINE$81,363
R29 · FY2000 · AI